NICE rejects Roche's Tecentriq in new lung cancer use

NICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a treatment for a kind of advanced lung cancer, citing “highly uncertain” data about the d

Lilly claims another victory in Alimta patent defence

AZ, Merck add pancreatic cancer to Lynparza’s growing use li...

J&J to buy US biotech Taris and its bladder cancer drug devi...

Johnson & Johnson is to buy the privately-owned biotech Taris, and a device that can deliver cancer drugs to the bladder.

FDA hastily approves Daiichi Sankyo/AZ's cancer drug, weeks ...

The FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time.

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lu...

Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.